1. Home
  2. ABVC vs CELU Comparison

ABVC vs CELU Comparison

Compare ABVC & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ABVC BioPharma Inc.

ABVC

ABVC BioPharma Inc.

HOLD

Current Price

$1.08

Market Cap

30.9M

Sector

Health Care

ML Signal

HOLD

Logo Celularity Inc.

CELU

Celularity Inc.

HOLD

Current Price

$1.31

Market Cap

36.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ABVC
CELU
Founded
2015
2016
Country
United States
United States
Employees
N/A
123
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
30.9M
36.0M
IPO Year
2009
N/A

Fundamental Metrics

Financial Performance
Metric
ABVC
CELU
Price
$1.08
$1.31
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
48.5K
101.3K
Earning Date
03-03-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
7.14
N/A
EPS
N/A
N/A
Revenue
$509,589.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$76.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.74
$1.01
52 Week High
$4.02
$4.35

Technical Indicators

Market Signals
Indicator
ABVC
CELU
Relative Strength Index (RSI) 35.36 54.82
Support Level N/A $1.25
Resistance Level $1.67 $1.33
Average True Range (ATR) 0.12 0.07
MACD -0.01 0.01
Stochastic Oscillator 29.19 81.08

Price Performance

Historical Comparison
ABVC
CELU

About ABVC ABVC BioPharma Inc.

ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.

About CELU Celularity Inc.

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

Share on Social Networks: